Tool Identifies Alcohol Relapse Risk After Liver Transplant Tool Identifies Alcohol Relapse Risk After Liver Transplant
A novel prognostic tool based on social determinants effectively predicted increased risk of alcohol use relapse in adults who underwent liver transplants for alcoholic liver disease.MDedge News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 1, 2023 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis (NASH). NASH, a progressive liver disease closely associated with…#taipei #taiwan #sandiego #polarisgroup #nash #adipeg20 #adipeg #howardchen #pegargiminase #bla (Source: Reuters: Health)
Source: Reuters: Health - November 30, 2023 Category: Consumer Health News Source Type: news
EXCLUSIVE: Ill, thin and broken, ex-England footballer Kieron Dyer, 44, was dying with a rare liver disease just 11 weeks ago. Now, he speaks for the first time after a 'miracle' transplant gave him a second shot at life
OLIVER HOLT: Kieron Dyer's version of A Christmas Carol has seen him get a second shot at life alongside wife, Holly, following a life-saving liver transplant. (Source: the Mail online | Health)
Source: the Mail online | Health - November 27, 2023 Category: Consumer Health News Source Type: news
Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
Elecsys ® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory results and clinical information.The single test will inform clinicians if treatment is required and regimens are working in conjunction with other diagnostic assays.Almost 300 million people globally have chronic hepatitis B, causing a significant burden to health systems as it puts patients at high risk of death from cirrhosis and liver cancer.1Basel, 27 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the la...
Source: Roche Media News - November 27, 2023 Category: Pharmaceuticals Source Type: news
Patients with existing health issues are at a higher risk of sepsis, researchers say
The research found those from deprived communities and victims of health issues such as chronic liver disease and chronic kidney disease were more at risk of developing sepsis (Source: the Mail online | Health)
Source: the Mail online | Health - November 24, 2023 Category: Consumer Health News Source Type: news
Prevalence of NAFLD Set to Increase to 34.3 Percent in 2050
MONDAY, Nov. 20, 2023 -- The burden of nonalcoholic fatty liver disease (NAFLD) is predicted to continue increasing, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Low-Dose Aspirin Reduces Liver Fat, Inflammation Markers Low-Dose Aspirin Reduces Liver Fat, Inflammation Markers
A single daily low dose of aspirin significantly reduced hepatic fat fraction and liver transaminase levels in a randomized trial in patients with metabolic-associated steatotic liver disease.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 16, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Experimental Weight-Loss Drug, Retatrutide, Slashed Fat in Livers of Obese People
WEDNESDAY, Nov. 15, 2023 -- Retatrutide, an experimental weight-loss drug that could compete against blockbusters Wegovy and Zepbound, may work wonders for obese folks with liver disease, new research shows.
A wider study, published in June, found... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 15, 2023 Category: General Medicine Source Type: news
East Bay company's 'greatest biotech comeback' drives toward drug approval in rare liver disease
The company was forced in late 2019 to ice clinical trials of its lead drug in a rare, but severe liver disease; it now hopes to ask the FDA early next year to approve the drug. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 14, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Ultrasound platform effective evaluating hepatic steatosis
Thursday, November 30 | 1:30 p.m.-1:40 p.m. | R6-SSGI19-1 | Room E352Attendees will hear about the potential for ultrasound-derived fat fraction to be an alternative tool for MRI in assessing hepatic steatosis.Yi Dong, MD, from Fudan University in Shanghai, China, will present findings that show how ultrasound-derived fat fraction can detect hepatic steatosis using MRI-derived proton density fat fraction as the reference standard.Several ultrasound platforms now provide quantitative measures of hepatic steatosis. One of these is ultrasound-derived fat fraction, which combines attenuation and backscatter quantification. ...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 Ultrasound Preview Source Type: news
MASLD Predicted to Increase by 23% by Middle of the Century
(MedPage Today) -- BOSTON -- A mathematical model predicts that the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) -- formerly known as nonalcoholic fatty liver disease (NAFLD) -- will substantially increase... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 12, 2023 Category: Gastroenterology Source Type: news
Engineering stem cells to treat liver disease
During clinical rotations in medical school, Kianna Nguyen encountered many patients with liver failure and was struck by a grim reality: Their only hope was a transplant. The shortage of donor organs and therapeutic options was at once frustrating and inspirational, triggering her research interest in cellular therapies for liver failure. Kianna Nguyen "Research provides us with the understanding to develop tools to make big changes in clinical problems like those facing patients with liver failure," says… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 11, 2023 Category: Databases & Libraries Source Type: news
Torrent, Zydus in co-marketing pact for liver disease drug Saroglitazar
Torrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment for Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. Under the agreement, Torrent gains semi-exclusive rights to market as VORXAR while Zydus continues marketing as Lipaglyn and Bilypsa. Licensing fees and milestone payments are part of the pact. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 10, 2023 Category: Pharmaceuticals Source Type: news
Food Insecurity Linked to MASLD in Adolescents Food Insecurity Linked to MASLD in Adolescents
National survey data revealed a significant association between metabolic dysfunction-associated liver disease in patients aged 12-18 years and food insufficiency.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 9, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Top Gastroenterology and Liver Disease Specialist, Dr. David P. Yamini, Receives Castle Connolly's 2023 Top Doctor ® Award
Recipients of this prestigious award were nominated by their peers, and it is a highly selective list. Those who are among the very best in their specialties are chosen for inclusion. BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 9, 2023 Category: Pharmaceuticals Tags: AWD Source Type: news
